Overview

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
Phase:
PHASE2
Details
Lead Sponsor:
Elixiron Immunotherapeutics (Hong Kong) Ltd.